Abstract

The Research Resource Technical Development Component is a dedicated vehicle for identification, development,standardization and dissemination of specialized assays and technologies which will be made available to the researchcommunity for human immunology studies. While the immediate application is orthopox-related, a general strategy forevaluating robust protective human T and B cell responses is offered. The RRTDC of this cooperative center will becomposed of eight components: 1) bioinformatics; 2) recombinant protein expression facility; 3) monoclonal antibodyproduction, purification and analysis facility; 4) automated functional assay analysis; 5) TCR repertoire analysis byhigh throughput DNA sequencing at the single cell level; 6) cutaneous resource to establish cell and organotypic skincultures; 7) a Serex-based vaccinia/MVA phage display for human antibody screening; and 8) biomarker libraryresource. A set of well-defined scientific milestones and periodic evaluations of scientific progress with respect tothose milestones are offered.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
3U19AI057330-05S1
Application #
7698932
Study Section
Special Emphasis Panel (ZAI1-PTM-I (M4))
Project Start
2008-05-20
Project End
2009-03-31
Budget Start
2008-05-20
Budget End
2009-03-31
Support Year
5
Fiscal Year
2008
Total Cost
$727,845
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Walsh, Stephen R; Wilck, Marissa B; Dominguez, David J et al. (2013) Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. J Infect Dis 207:1888-97
Walsh, Stephen R; Seaman, Michael S; Grandpre, Lauren E et al. (2012) Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine 31:114-9
Seedhom, Mina O; Mathurin, Keisha S; Kim, Sung-Kwon et al. (2012) Increased protection from vaccinia virus infection in mice genetically prone to lymphoproliferative disorders. J Virol 86:6010-22
Zhang, Guang Lan; DeLuca, David S; Keskin, Derin B et al. (2011) MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles. J Immunol Methods 374:53-61
Zhang, Guang Lan; Lin, Hong Huang; Keskin, Derin B et al. (2011) Dana-Farber repository for machine learning in immunology. J Immunol Methods 374:18-25
Reinhold, Bruce; Keskin, Derin B; Reinherz, Ellis L (2010) Molecular detection of targeted major histocompatibility complex I-bound peptides using a probabilistic measure and nanospray MS3 on a hybrid quadrupole-linear ion trap. Anal Chem 82:9090-9
Welsh, Raymond M; Che, Jenny W; Brehm, Michael A et al. (2010) Heterologous immunity between viruses. Immunol Rev 235:244-66
Wilck, Marissa B; Seaman, Michael S; Baden, Lindsey R et al. (2010) Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 201:1361-70
Liu, Luzheng; Zhong, Qiong; Tian, Tian et al. (2010) Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 16:224-7
Seaman, Michael S; Wilck, Marissa B; Baden, Lindsey R et al. (2010) Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis 201:1353-60

Showing the most recent 10 out of 20 publications